ALTIMMUNE, INC. Deferred Revenue
ALTIMMUNE, INC. (ALT) had Deferred Revenue of $19.75 thousand as of 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2021-11-09
- 2021-09-30: Deferred Revenue, Current $19.75K.
- 2021-06-30: Deferred Revenue, Current $57.99K.
- 2021-03-31: Deferred Revenue, Current $19.75K.
- 2020-12-31: Deferred Revenue, Current $19.75K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2021-09-30 | $19.75K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $57.99K 10-Q · filed 2021-08-10 |
| 2021-03-31 | $19.75K 10-Q · filed 2021-05-17 |
| 2020-12-31 | $19.75K 10-Q · filed 2021-11-09 |
| 2020-09-30 | $19.75K 10-Q · filed 2020-11-09 |
| 2020-06-30 | $33.69K 10-Q · filed 2020-08-11 |
| 2020-03-31 | $47.63K 10-Q · filed 2020-05-13 |
| 2019-12-31 | $61.56K 10-K · filed 2021-02-25 |
| 2019-09-30 | $19.75K 10-Q · filed 2019-11-13 |
| 2019-06-30 | $32.44K 10-Q · filed 2019-08-13 |
| 2019-03-31 | $41.87K 10-Q · filed 2019-05-14 |
| 2018-12-31 | $19.75K 10-K · filed 2020-03-27 |
| 2018-09-30 | $19.75K 10-Q · filed 2018-11-13 |
| 2018-06-30 | $32.25K 10-Q · filed 2018-08-14 |
| 2018-03-31 | $44.75K 10-Q · filed 2018-05-15 |
| 2017-12-31 | $19.75K 10-K · filed 2019-04-01 |
| 2017-09-30 | $19.75K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $32.25K 10-Q · filed 2017-08-14 |
| 2016-12-31 | $19.75K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |